Q&A With Mark Freedman, MD, of Ottawa Hospital: Developing Medication for Multiple Sclerosis a Long and Complicated Process

Medications in general can take a long time to develop. Depending on the condition they treat that process can be even longer as more questions have to be answered before they can be introduced to the field. This is particularly true of multiple sclerosis treatments.

Mark Freedman, MD, FAAN, from Ottawa Hospital discussed some of the steps that needed to be taken before teriflunomide was approved including requirements by different regulatory entities. Freedman also discussed the safety profile of the medication which is used to treat patients with the relapsing form of the condition and work shown to prove that the therapy is effective in various patient groups.